Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

1상 완료 NCT05541861

요약

This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to select a safe and tolerable dose and to evaluate BNT162b4 + BNT162b2 Bivalent (original/Omicron BA.4/BA.5) when given as Dose 1 and Dose 2 (booster) in Cohorts 1 and 2 and BNT162b4 + BNT162b2 Monovalent (OMI XBB.1.5) when given as Dose 2 (booster) in Cohorts 3a, 3b, 4a, and 4b, and 30 microgram (mcg) BNT162b4 when given alone as Dose 1 and Dose 2 in Cohort 5. The trial used a staggered dosing process schema, i.e., enrollment into the next higher dose level was done sequentially and subject to safety data from the previous dose levels, with sentinel participants in Cohorts 1, 2, 3a, and 4a. Cohort 3b investigating the same dose level as cohort 3a but in participants aged \>55 years was opened after safety data for participants aged 18-55 years in Cohort 3a had been reviewed. Enrollment into Cohorts 4a and 4b was opened after safety data for Cohort 3a and 3b had been reviewed. Cohort 5 participants were not randomized and received two doses of BNT162b4 alone afte

Number of Participants With Solicited Local Reactions- Post Dose 1

Up to 7 days post-dose1 · Participants

Number of Participants With Solicited Local Reactions- Post Dose 2

Up to 7 days post-dose 2 · Participants

Number of Participants With Solicited Systemic Events- Post Dose 1

Up to 7 days post-dose 1 · Participants

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

전체 임상